- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00436605
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
A Phase 2 Study of Dasatinib in Advanced Melanoma
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. Determine the objective response rate in patients with stage III unresectable or stage IV melanoma treated with dasatinib.
II. Determine the progression-free survival of patients treated with this drug.
SECONDARY OBJECTIVES:
I. To assess the expression of targets of Dasatinib prior to treatment by obtaining pre-treatment biopsies or examining paraffin-embedded tissues from previous tumor resections.
II. In selected patients (approximately 5-10) where tumor tissue is available pre-treatment and can be obtained post-treatment with Dasatinib (21 days after initiation of therapy), to determine if Dasatinib induces changes in expression of selected targets and downstream mediators, including MEK, ERK and RSK-1.
III. To assess toxicity.
OUTLINE:
Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06520
- Yale University
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Masonic Cancer Center, University of Minnesota
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically confirmed stage III unresectable or stage IV melanoma
- Measurable disease
- Must have evidence of tumor growth or new lesions within the past 6 months
- No large pleural effusions
No known brain metastases or leptomeningeal metastases
- Previously treated brain metastases allowed provided there is no requirement for steroids AND no evidence of progression for ≥ 8 weeks after treatment
- ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%
- Life expectancy > 3 months
- WBC ≥ 3,000/mm³
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 9.0 g/dL (transfusions allowed)
- Bilirubin ≤ 1.5 mg/mL
- AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- PT/INR and PTT normal
- Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
No medical condition that may affect the ability to swallow and retain dasatinib tablets, including any of the following:
- Gastrointestinal tract disease resulting in an inability to take oral medication
- Requirement for IV alimentation
- Prior surgical procedures affecting absorption
- Active peptic ulcer disease
No clinically significant cardiovascular disease, including any of the following:
- Myocardial infarction or ventricular tachyarrhythmia within the past 6 months
- Prolonged QTc > 480 msec
- Major conduction abnormality (unless a cardiac pacemaker is present)
No uncontrolled intercurrent illness including, but not limited to, any of the following:
- Ongoing or active infection
History of significant congenital or acquired bleeding disorder, including any of the following:
- Von Willebrand's disease
- Antifactor VIII antibodies
- Dyspnea at rest or with minimal exertion
- Uncontrolled seizure disorder
- Psychiatric illness or social situations that would preclude study compliance
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No other active malignancy within the past 3 years except curatively treated stage I malignancies or resected skin carcinomas
- Recovered from prior therapy
- Prior adjuvant therapy for stage II or III melanoma allowed
- No prior cytotoxic therapy for metastatic melanoma
- No prior dasatinib or other inhibitors of src, bcr-abl, c-Kit, EPHA2, and PDGFRβ
- No more than 2 prior immunomodulator therapies for metastatic melanoma
- At least 1 week since prior and no concurrent warfarin or other anticoagulants or medications that inhibit platelet function (including acetylsalicylic acid)
At least 1 week since prior and no concurrent steroids or other immunosuppressive agents
- Concurrent steroids to treat induced pleural effusions allowed
At least 3 weeks since prior immunomodulators including, but not limited to, any of the following:
- Aldesleukin
- Cancer vaccines
- T-cell-activating monoclonal antibodies
At least 4 weeks since prior radiotherapy
- Prior palliative radiotherapy to a single site of disease allowed (tumor is not considered evaluable for response unless there is tumor progression at the site of radiation)
- More than 7 days since prior and no concurrent CYP3A4 inhibitors
- At least 7 days since prior and no concurrent agents with proarrhythmic potential
- No other concurrent investigational agents
- No other concurrent anticancer agents or therapies
- No concurrent enzyme-inducing anticonvulsant agents
- No concurrent grapefruit or grapefruit juice
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No concurrent CYP3A4 inducers
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Treatment (kinase inhibitor therapy)
Patients receive oral dasatinib twice daily on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Subjects With Objective Response(Partial Response and Complete Response) as Measured by RECIST Criteria
Lasso di tempo: After every 8 weeks (or 2 courses), assessed up to 4 weeks after completion of treatment
|
Only those patients who have measurable disease present at baseline, have received at least one course of therapy, and have had their disease re-evaluated will be considered evaluable for response.
A Simon's optimum two-stage design will be used.
|
After every 8 weeks (or 2 courses), assessed up to 4 weeks after completion of treatment
|
Progression-free Survival
Lasso di tempo: Time from start treatment to time of progression, assessed up to 6 months
|
Progression will be evaluated in this study using the new international criteria proposed by the RECIST Committee.
A Simon's optimum two-stage design will be used
|
Time from start treatment to time of progression, assessed up to 6 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Harriet Kluger, Yale University
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Neoplasie
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Tumori neuroendocrini
- Nevi e melanomi
- Melanoma
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Inibitori della chinasi proteica
- Dasatinib
Altri numeri di identificazione dello studio
- NCI-2009-00219 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- CDR0000528937
- UMN-2007UC009
- YALE-HIC-0608001765
- HIC#0608001765 (Altro identificatore: Yale University)
- 7758 (Altro identificatore: CTEP)
- P30CA016359 (Sovvenzione/contratto NIH degli Stati Uniti)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su dasatinib
-
Bristol-Myers SquibbCompletatoStudio di farmacocinetica in partecipanti saniStati Uniti
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completato
-
Hyoung Jin KangNon ancora reclutamentoLeucemia linfoblastica acuta, pediatrica
-
National Cancer Institute (NCI)RitiratoNeoplasie a cellule emopoietiche e linfoidi | Linfoma avanzato | Neoplasia solida maligna avanzata | Linfoma refrattario | Neoplasia solida maligna refrattaria | Mieloma plasmacellulare refrattarioStati Uniti
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedCompletato
-
National Cancer Institute (NCI)NRG OncologyTerminatoCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Cistodenocarcinoma ovarico a cellule chiare | Adenocarcinoma endometriale a cellule chiare | Cancro del corpo uterino ricorrenteStati Uniti
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbCompletato
-
Peking University Cancer Hospital & InstituteSconosciutoTumore stromale gastrointestinaleCina
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletatoCancro ai polmoniStati Uniti
-
Kanto CML Study GroupSconosciutoLeucemia Mieloide, Cronica, Fase CronicaGiappone